CARDIOVASCULAR DISEASE IS THE NUMBER ONE CAUSE OF DEATH IN BOTH MEN AND WOMEN, BUT A NEW FDA APPROVAL FOR A MEDICATION COULD REDUCE CARDIOVASCULAR HEALTH RISKS AND BENEFIT MILLIONS OF AMERICANS. JOINING US TODAY TO DISCUSS THIS NEW MEDICATION IS DR. DEEPAK BHATT, EXECUTIVE DIRECTOR OF INTERVENTIONAL CARDIOVASCULAR PROGRAMS AT BRIGHAM AND WOMEN’S HOSPITAL.
For more information visit: VASCEPA.com
About Dr. Deepak Bhatt
Dr. Deepak L. Bhatt is the executive director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital, professor of medicine at Harvard Medical School, and editor-in-chief of the Harvard Heart Letter. He was also the lead investigator of the REDUCE-IT study which served as the basis for the new FDA approval for VASCEPA. Dr. Bhatt specializes in cardiovascular medicine and interventional cardiology. The author of over 1,000 peer-reviewed publications, Dr. Bhatt is listed as a Clarivate Highly Cited Researcher. He is the editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease. Three projects he helped lead were listed in the 2014 American Heart Association/American Stroke Association top ten advances in heart disease and stroke research. He is a former trustee of the American College of Cardiology.
